Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Surface Oncology enters licence agreement to use Ligand’s OmniAb platform

pharmaceutical-technologyJune 06, 2017

Tag: Surface Oncology , Ligand’s OmniAb platform , Biotechnology

PharmaSources Customer Service